Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
1998-10-09
2001-07-24
Low, Christopher S. F. (Department: 1652)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C514S002600, C514S012200, C530S380000, C530S395000, C424S184100
Reexamination Certificate
active
06264953
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to the preparation and use of zona pellucida (ZP) antigens and monoclonal antibodies for contraception or sterilization in individuals. The present invention also relates to immunological contraception. More specifically, the present invention relates to immunological contraception utilizing zona pellucida antigens produced by recombinant DNA technology to actively immunize an individual against pregnancy, or monoclonal antibodies prepared against the zona pellucida antigens to passively immunize the individual. In addition, the present invention relates to the use of anti-idiotypic monoclonal antibodies which would mimic ZP antigens to actively immunize an individual against pregnancy.
This invention also relates to monoclonal anti-zona pellucida antibody, to novel hybridoma cells which express such antibody, and to a method for producing such hybrid cells and anti-zona pellucida antibody.
2. Brief Description of the Background Art
The zona pellucida is the complex extracellular glycoprotein matrix which surrounds the mammalian oocyte. This matrix is formed during the early stages of oocyte growth and follicular cell differentiation and serves to protect the oocyte and embryo until implantation in the uterine wall (Austin, et al.,
Reproduction in Mammals: Germ Cells and Fertilization
, Cambridge Univ. Press, Cambridge, England (1982)). In addition, the zona pellucida plays an important role in the fertilization process since the sperm must first adhere to and penetrate the zona pellucida. After binding to the zona pellucida of an oocyte, the sperm must penetrate the zona pellucida. Sperm penetration of the zona pellucida is probably mediated by the limited hydrolysis of zona pellucida components by sperm enzymes such as acrosin (McRorie et al.,
Ann. Rev. Biochem.
43: 777 (1974); Dunbar et al.,
Biol. Reprod.
32:619 (1985), and Stambaugh,
Gam. Res.
1:65, 1978). The zona pellucida remains intact after fertilization, to ensure proper embryonic development and perhaps to prevent embryo fusion in the oviduct (Mintz,
Science
138:594, 1962).
Finally, the zona pellucida plays a role in the block to polyspermy. In some mammalian species, fertilization alters sperm binding to the zona and its resistance to proteolytic digestion (Austin and Braden,
J. Exp. Biol.
33:358, 1956).
There are major biological, morphological, physiological and immunochemical variations in properties among the zona pellucida of rodents as compared with the zona pellucida of other species including sub-human primates and humans. See reviews by Dunbar, In
Mechanism and Control of Fertilization
(J. Hartmann, ed.), Academic Press, New York, pp. 139 (1983); Dunbar, In
International Congress on Reproductive Immunology
(Wegmann and Gill III, eds.), Oxford Univ. Press, London, pp. 505 (1983) and Dunbar et al., In:
Modern Cell Biology
3, (Satir. ed.) Alan R. Liss, New York, pp. 77 (1984). Although mammalian zona pellucida is composed of a limited number of major glycoproteins (Bleil et al.,
Dev. Biol.
76:185 (1980); Dunbar et al.,
Biol. Reprod.
24:1111 (1981); Timmons and Dunbar,
Biol. Reprod.
(1987)), the structural and functional relationships of zona pellucida proteins of different species vary.
Attempts to develop an effective and economical method of immunocontraception have been hindered by the lack of sufficient material to produce quantities of antigen or antibodies needed to produce a vaccine which would either inhibit fertilization of the oocyte by the sperm, prevent implantation of a fertilized egg, or prevent the development of the ovaries thereby making the animal permanently sterile. Early attempts to develop immunocontraceptive methods have not been very successful. These attempts have included the use of naturally occurring circulating peptide hormones such as human chorionic gonadotrophin (hCG) and follicle stimulating hormone (Griffin, In
Immunological Approaches to Contraception and Promotion of Fertility
, G. P. Talwan, Ed., Plenum Press, New York (1986)). Immunocontraception utilizing antibodies against normally “circulating” antigens poses the problem that immune complexes might form which would bring about undesirable tissue damage. Furthermore, immunization with “circulating” antigens has not proven totally effective in inhibiting fertility.
Immunologically based methods of contraception are preferable to other commercially available methods such as surgical sterilization or birth control pills (for humans and pets) in which there is a continuous expense for medication which must be used and purchased on a regular basis and are only indicated for use on a temporary basis. Thus, a considerable need exists for antigen preparations that can induce transient or permanent contraception in an individual and which can be provided in a safe, reliable and cost effective manner.
SUMMARY OF THE INVENTION
The work of the inventor has focused on the use of purified zona pellucida antigens for immunological sterilization or contraception. Immunization with zona pellucida antigens has distinct advantages over other immunological contraceptive methods. Immunocontraception with zona pellucida antigens can be designed so that it is not abortive but instead inhibits fertilization. This is particularly desirable for immunocontraception in humans. In addition, this method may be modified so that ovarian follicular development is inhibited causing permanent sterilization. This modification will allow non-surgical sterilization of pets and other animals without the concurrent surgical risks and expense.
Another distinct advantage to zona pellucida protein immunocontraception is the fact that low liters of zona pellucida antibodies will block fertilization. This is due to the localized and specific nature of the site of action of the immunocontraceptive antibody and the limited occurrence of naturally occurring zona pellucida protein in the individual in which fertilization is to be blocked. The zona antigens studied to date are tissue specific and are fixed in the ovary so they do not circulate. In contrast, the hormone proteins circulate throughout the individual, occur at much higher levels, and the levels of circulating antigen vary greatly depending upon the physiological state of the individual. In addition, the levels of sperm antigens which must be blocked for sperm antigen immunocontraception to be efficient is variable, being dependent upon the amount of sperm in the vaginal canal and uterine cavity.
Since the ZP proteins of a variety of animal species are immunologically crossreactive, the necessity for developing an immunizing antigen for each species in which contraception is desired is obviated.
One object of the present invention was the development of an effective immunological method of contraception which (1) requires only one (or minimal) numbers of administrations and therefore does not require the continuous need for a physician (if human use) or veterinarian (if animal use) and (2) can be designed to induce permanent sterilization or castration (desirable in pets) or transient infertility (desirable in humans as well as breeding pets).
One of the disadvantages prior to the present invention was the limited supply of zona pellucida antigens and antibodies to use for immunocontraception. The present invention provides a plentiful readily available source of zona pellucida antigens and antibodies for immunocontraception by providing zona pellucida antigens produced by recombinant DNA technology and monoclonal zona pellucida antibodies and ZP anti-idiotypic antibodies. This provides an additional cost effective advantage since antigens and antibodies are able to be manufactured on a large cost effective scale using recombinant DNA and hybridoma technology.
The present invention relates to antigenic preparations and methods of immunizing an animal to induce antibodies which react with epitopic determinants found on zona pellucida antigens. This invention also relates to monoclonal anti-zona pelluc
Bugaisky Gabriele E.
Low Christopher S. F.
Marshall O'Toole Gerstein Murray & Borun
Zonagen, Inc.
LandOfFree
Method of preparation and use for zona pellucida antigens... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of preparation and use for zona pellucida antigens..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of preparation and use for zona pellucida antigens... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2481007